Biologics Safety Testing Market worth $6.8 billion | Opportunities, Key Players, Competitive and Regional Analysis

The global biologics safety testing market is projected to reach USD 6.8 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 13.3% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growing developments of biologics and biosimilars, increased concerns over the cell culture contamination, and rising investments in biopharmaceutical research and development.

Get Access to Sample Pages + Covid-19 impact analysis:

Key Market Players

Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Labcorp (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Sartorius AG (Germany), and Lonza (Switzerland).


Charles River is one of the key players in the biologics safety testing market. It is a service and early-stage contract research organization (CRO). The company develops a diverse portfolio of discovery & safety assessment services by providing a suite of products and services to support its clients’ manufacturing activities. The company operates through three reporting segments, namely, Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).


Lonza is a key player in the biologics safety testing market. The company has a large number of manufacturing and R&D facilities worldwide. The company’s wide geographic presence and high production capacity deliver quality products worldwide.


Thermo Fisher Scientific offers analytical instruments, equipment, reagents, and consumables for research, discovery, analysis, diagnostics, and manufacturing. The company operates through four principal product segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

For In-Depth Competitive Analysis, Read a Report: @

The Asia Pacific region is the fastest growing region of the Biologics safety testing market

The Asia Pacific market is projected to witness the highest growth rate during the forecast period. Rapid growth in outsourcing preclinical, clinical, and laboratory testing services to APAC countries is expected to drive market growth during the forecast period. Several companies are focusing on increasing their market shares and customer base in the region to capitalize on these opportunities in the Asia Pacific market.

Recent Developments

  • Merck KGaA (Germany) invested in expanding its biosafety testing capacity at Rockville, Maryland, US. This site will provide biosafety testing and analytical development services in the US.
  • Eurofins Scientific (Luxembourg) acquired Wessling Hungary, a food, environmental, and BioPharma product testing laboratory in Hungary. This acquisition helped expand Eurofins’ biopharma testing business in Europe.
  • Lonza (Switzerland) launched the PyroCell Monocyte Activation Test to detect non-endotoxin pyrogens and reduce interferences from complex drug products, such as biologics-based pharmaceuticals.

Buy-Now this Premium Report @